Pfizer sets pricing for COVID-19 vaccine

Pfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free.

Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots.

The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. The Affordable Care Act requires insurers to cover many recommended vaccines without charging any out-ofpocket expenses.

A spokesman said the company also has an income-based assistance program that helps eligible U.S. residents with no insurance to get the shots.

A Pfizer executive said Thursday that the price reflects increased costs for switching to single-dose vials and commercial distribution. The executive, Angela Lukin, said the price was well below the thresholds “for what would be considered a highly effective vaccine.”

Pfizer’s two-shot vaccine debuted in late 2020 and is easily the most common preventive shot that has been used to fight COVID-19 in the U.S.

More than 375 million doses of the original vaccine have been distributed in the U.S., according to the Centers for Disease Control and Prevention.

That doesn’t count another 12 million doses of an updated booster that was approved earlier this year.

The vaccine brought in $36.8 billion in revenue last year for Pfizer.